Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What are the lessons of Lipitor's patent expiry in the US?

This article was originally published in Scrip

Executive Summary

Lipitor’s patent expiry this year is the most anticipated end ever for a branded drug. It is not every year that the most successful drug in pharmaceutical industry history succumbs to generic competition and retires from the commercial limelight. Indeed, it seems like forever since people involved in the pharmaceutical industry, healthcare, medical policy, or you name it have been talking about this expiry.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel